25% Investment Upside - Positive Cancer Treatment News is Driving This Stock

Quick investment opportunity based on recent news. Trading Overview Entry Price should be around $2.00 Target Price should be around $2.50 Set a stop loss of 5% ($1.90) Recent news about OncoCyte's drug Determarx shows signs to help battle lung cancer. Trials will start with patients this quarter and the company is presenting its findings at the North American Conference for Lung Cancer.

back

25% Investment Upside - Positive Cancer Treatment News is Driving This Stock

bullish
Quick investment opportunity based on recent news. Trading Overview Entry Price should be around $2.00 Target Price should be around $2.50 Set a stop loss of 5% ($1.90) Recent news about OncoCyte's drug Determarx shows signs to help battle lung cancer. Trials will start with patients this quarter and the company is presenting its findings at the North American Conference for Lung Cancer.
Comments

Write your comment....

Sign in to comment

read-time
< 1 min

2.50

Target Price

6/ 10

Confidence

< 1 Week

Timeframe
Share
catalyst icon
Earnings Per Share
catalyst icon
Financials
catalyst icon
Management
catalyst icon
Price to Earnings Ratio
catalyst icon
Dividend
catalyst icon
Other Catalyst

OCX Channel

Start new chat
aiodd-ad
next